West Pharmaceutical Services to Announce Q4 2025 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 13 2025
0mins
Should l Buy WST?
Source: NASDAQ.COM
West Pharmaceutical Services Inc. (WST) experienced a decline of 3.37% and hit a 20-day low amid broader market weakness, with the Nasdaq-100 down 0.56% and the S&P 500 down 0.27%.
The company is set to release its Q4 and full-year 2025 financial results on February 12, 2026, which is expected to significantly impact investor sentiment. Following the earnings release, a conference call will be held to discuss the results and business expectations. In fiscal year 2024, West generated $2.89 billion in net sales, reinforcing its position as a leading provider of innovative injectable solutions.
This upcoming earnings report could provide critical insights into the company's performance and future outlook, potentially influencing stock movement in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 248.950
Low
285.00
Averages
348.70
High
375.00
Current: 248.950
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, with advance registration required for participants to ask questions.
- Investor Resources: A slide presentation will be made available on the day of the call in the Investors section of the company's website, ensuring that investors have access to critical information to support their decision-making.
- Company Overview: In fiscal year 2024, West generated $2.89 billion in net sales, positioning itself as a leading provider of innovative injectable solutions, delivering over 41 billion components and devices annually, which underscores its strong market presence.
See More
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to impact investor confidence.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, offering participants the option to register in advance for questions.
- Investor Resources: A slide presentation will be made available on the company's website in the Investors section on the day of the call, ensuring that investors can access key information to make informed decisions.
- Company Background: West Pharmaceutical Services generated $2.89 billion in net sales in fiscal year 2024, and as a leading provider of injectable drug solutions, supports customers in delivering over 41 billion components and devices annually.
See More
West Pharmaceutical and Others Set for Ex-Dividend Trading
- West Pharmaceutical Ex-Dividend: West Pharmaceutical Services, Inc. (WST) will trade ex-dividend on January 28, 2026, with a quarterly dividend of $0.22, leading to an expected price drop of approximately 0.09%, indicating a stable dividend payment history.
- Heritage Financial Dividend Update: Heritage Financial Corp (HFWA) is set to pay a quarterly dividend of $0.24 on February 11, 2026, with an anticipated price drop of about 0.90%, reflecting a relatively high annual yield of 3.61%.
- Entegris Dividend Details: Entegris Inc (ENTG) will pay a quarterly dividend of $0.10 on February 18, 2026, with an expected price decline of around 0.09%, showing a stable annual yield of 0.35%.
- Market Performance Overview: On Monday, shares of West Pharmaceutical, Heritage Financial, and Entegris fell by approximately 4.5%, 5.5%, and 3.2%, respectively, indicating market reactions to the upcoming ex-dividend dates.
See More
AeroVironment (AVAV) Drops 19.45% After US Government Stops SCAR Program Work
- AeroVironment Decline: AeroVironment's stock plummeted 19.45% this week after the US government issued a stop work order on the SCAR program, which could significantly hinder its future revenue and project timelines.
- DraftKings Legal Challenge: DraftKings fell 14.4% this week as a Massachusetts judge allowed the state to block Kalshi from offering sports-related contracts, potentially limiting DraftKings' market share in the state.
- Abbott Sales Miss: Abbott Laboratories' stock dropped 12.23% this week after reporting fourth-quarter sales results that fell short of expectations, along with first-quarter adjusted EPS guidance below analyst estimates, which may undermine investor confidence.
- Flutter Entertainment Downgrade: Flutter Entertainment's stock decreased 13.07% this week as multiple analysts lowered their price forecasts, reflecting market concerns about its future growth prospects.
See More
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
- Market Performance: The Dow Jones Industrial Average rose by 2.5% and closed above 50,000 for the first time.
- Nasdaq Struggles: In contrast, the Nasdaq Composite ended the week down 1.8%, despite a strong rally on Friday.
See More
U.S. Jobs and Inflation Data Set for Release
- Job Data Expectations: The U.S. is expected to add 60,000 jobs in January, up from 50,000 in December, which could influence the Fed's monetary policy direction amidst ongoing economic uncertainty.
- Inflation Metrics Analysis: The January Consumer Price Index is projected to rise by 0.29% month-over-month and 2.5% year-over-year, showing improvement but still falling short of the Fed's 2% target, potentially affecting investor rate expectations.
- Market Reaction and Risks: Recent signs of labor market weakness, including an ADP report indicating only 22,000 new private sector jobs, may heighten expectations for further Fed rate cuts, although investors remain optimistic about economic resilience.
- Stock Market Rotation Trend: A significant rotation within the stock market is underway, with the Dow Jones Industrial Average rising over 2% this week, reflecting confidence in economic recovery, despite ongoing weakness in tech stocks.
See More
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, with advance registration required for participants to ask questions.
- Investor Resources: A slide presentation will be made available on the day of the call in the Investors section of the company's website, ensuring that investors have access to critical information to support their decision-making.
- Company Overview: In fiscal year 2024, West generated $2.89 billion in net sales, positioning itself as a leading provider of innovative injectable solutions, delivering over 41 billion components and devices annually, which underscores its strong market presence.
See More
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to impact investor confidence.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, offering participants the option to register in advance for questions.
- Investor Resources: A slide presentation will be made available on the company's website in the Investors section on the day of the call, ensuring that investors can access key information to make informed decisions.
- Company Background: West Pharmaceutical Services generated $2.89 billion in net sales in fiscal year 2024, and as a leading provider of injectable drug solutions, supports customers in delivering over 41 billion components and devices annually.
See More
West Pharmaceutical and Others Set for Ex-Dividend Trading
- West Pharmaceutical Ex-Dividend: West Pharmaceutical Services, Inc. (WST) will trade ex-dividend on January 28, 2026, with a quarterly dividend of $0.22, leading to an expected price drop of approximately 0.09%, indicating a stable dividend payment history.
- Heritage Financial Dividend Update: Heritage Financial Corp (HFWA) is set to pay a quarterly dividend of $0.24 on February 11, 2026, with an anticipated price drop of about 0.90%, reflecting a relatively high annual yield of 3.61%.
- Entegris Dividend Details: Entegris Inc (ENTG) will pay a quarterly dividend of $0.10 on February 18, 2026, with an expected price decline of around 0.09%, showing a stable annual yield of 0.35%.
- Market Performance Overview: On Monday, shares of West Pharmaceutical, Heritage Financial, and Entegris fell by approximately 4.5%, 5.5%, and 3.2%, respectively, indicating market reactions to the upcoming ex-dividend dates.
See More
AeroVironment (AVAV) Drops 19.45% After US Government Stops SCAR Program Work
- AeroVironment Decline: AeroVironment's stock plummeted 19.45% this week after the US government issued a stop work order on the SCAR program, which could significantly hinder its future revenue and project timelines.
- DraftKings Legal Challenge: DraftKings fell 14.4% this week as a Massachusetts judge allowed the state to block Kalshi from offering sports-related contracts, potentially limiting DraftKings' market share in the state.
- Abbott Sales Miss: Abbott Laboratories' stock dropped 12.23% this week after reporting fourth-quarter sales results that fell short of expectations, along with first-quarter adjusted EPS guidance below analyst estimates, which may undermine investor confidence.
- Flutter Entertainment Downgrade: Flutter Entertainment's stock decreased 13.07% this week as multiple analysts lowered their price forecasts, reflecting market concerns about its future growth prospects.
See More
